Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma

NCT00327327 is registered in ClinicalTrials.gov with AmpliMed Corporation as lead sponsor.

NCT NCT00327327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00327327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma
Lead sponsor
AmpliMed Corporation
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2004
Completion date
October 31, 2009
Enrollment
105 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma